Author: admin

Cholestatic Pruritus Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Escient Pharma, GlaxoSmithKline, Mirum Pharma, Albireo, Regeneron Pharma

DelveInsight’s “Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cholestatic Pruritus, historical and forecasted epidemiology as well as the Cholestatic Pruritus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cholestatic Pruritus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cholestatic Pruritus Market Forecast

Some of the key facts of the Cholestatic Pruritus Market Report: 

• The Cholestatic Pruritus market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• According to research conducted by Yoshikawa et al. in 2021, pruritus prevalence is documented at 70% among individuals with primary biliary cholangitis (PBC). Additionally, pruritus has been observed in 8% of patients with chronic hepatitis B and in approximately 2.5–20% of those with chronic hepatitis C.

• Pruritus is commonly linked to cholestatic liver conditions such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Review articles suggest an occurrence of pruritus in approximately 20–70% of individuals with PBC and in 38% of those affected by PSC.

• Key Cholestatic Pruritus Companies: Escient Pharmaceuticals, GlaxoSmithKline, Mirum Pharmaceuticals, Albireo, Regeneron Pharmaceuticals, Avior Bio, and others

• Key Cholestatic Pruritus Therapies: EP547, Linerixibat, LUM001, A4250, Dupilumab, AV104, and others

• The Cholestatic Pruritus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cholestatic Pruritus pipeline products will significantly revolutionize the Cholestatic Pruritus market dynamics.

Cholestatic Pruritus Overview

Cholestatic pruritus, also known as cholestatic itch, is a distressing symptom characterized by intense itching that occurs in individuals with cholestatic liver diseases. Cholestatic liver diseases are conditions where the flow of bile from the liver to the small intestine is impaired, leading to the accumulation of bile acids and other substances in the bloodstream.

Get a Free sample for the Cholestatic Pruritus Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/cholestatic-pruritus-market

Cholestatic Pruritus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cholestatic Pruritus Epidemiology Segmentation:

The Cholestatic Pruritus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Cholestatic Pruritus

• Prevalent Cases of Cholestatic Pruritus by severity

• Gender-specific Prevalence of Cholestatic Pruritus

• Diagnosed Cases of Episodic and Chronic Cholestatic Pruritus

Download the report to understand which factors are driving Cholestatic Pruritus epidemiology trends @ Cholestatic Pruritus Epidemiology Forecast

Cholestatic Pruritus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholestatic Pruritus market or expected to get launched during the study period. The analysis covers Cholestatic Pruritus market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cholestatic Pruritus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cholestatic Pruritus Therapies and Key Companies

• EP547: Escient Pharmaceuticals

• Linerixibat: GlaxoSmithKline

• LUM001: Mirum Pharmaceuticals

• A4250: Albireo

• Dupilumab: Regeneron Pharmaceuticals

• AV104: Avior Bio

Discover more about therapies set to grab major Cholestatic Pruritus market share @ Cholestatic Pruritus Treatment Landscape

Cholestatic Pruritus Market Strengths

• Increasing prevalence of Cholestatic Pruritus in the 7MM

• Complex underlying mechanisms have been identified and various therapeutic options developed.

Cholestatic Pruritus Market Opportunities

• Current treatments for cholestatic pruritus are inadequate, and additional, more effective therapeutic options are required.

Scope of the Cholestatic Pruritus Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Cholestatic Pruritus Companies: , and others

• Key Cholestatic Pruritus Therapies: EP547, Linerixibat, LUM001, A4250, Dupilumab, AV104, and others

• Cholestatic Pruritus Therapeutic Assessment: Cholestatic Pruritus current marketed and Cholestatic Pruritus emerging therapies

• Cholestatic Pruritus Market Dynamics: Cholestatic Pruritus market drivers and Cholestatic Pruritus market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Cholestatic Pruritus Unmet Needs, KOL’s views, Analyst’s views, Cholestatic Pruritus Market Access and Reimbursement 

To know more about Cholestatic Pruritus companies working in the treatment market, visit @ Cholestatic Pruritus Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Cholestatic Pruritus Market Report Introduction

2. Executive Summary for Cholestatic Pruritus

3. SWOT analysis of Cholestatic Pruritus

4. Cholestatic Pruritus Patient Share (%) Overview at a Glance

5. Cholestatic Pruritus Market Overview at a Glance

6. Cholestatic Pruritus Disease Background and Overview

7. Cholestatic Pruritus Epidemiology and Patient Population

8. Country-Specific Patient Population of Cholestatic Pruritus 

9. Cholestatic Pruritus Current Treatment and Medical Practices

10. Cholestatic Pruritus Unmet Needs

11. Cholestatic Pruritus Emerging Therapies

12. Cholestatic Pruritus Market Outlook

13. Country-Wise Cholestatic Pruritus Market Analysis (2019–2032)

14. Cholestatic Pruritus Market Access and Reimbursement of Therapies

15. Cholestatic Pruritus Market Drivers

16. Cholestatic Pruritus Market Barriers

17.  Cholestatic Pruritus Appendix

18. Cholestatic Pruritus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cholestatic Pruritus Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Escient Pharma, GlaxoSmithKline, Mirum Pharma, Albireo, Regeneron Pharma

DelveInsight’s “Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dermatomyositis Market Forecast

Some of the key facts of the Dermatomyositis Market Report: 

• The Dermatomyositis market size was valued approximately USD 230 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

• As per DelveInsight’s projections, within the 7MM, the United States dominated the dermatomyositis market, generating approximately USD 139.3 million in revenue in 2022. Subsequently, Japan, Germany, the UK, and other regions followed suit.

• DelveInsight’s projections suggest that in 2022, approximately 71,351 cases of diagnosed prevalent dermatomyositis were recorded across the 7MM. Among these cases, around 9% were juvenile while the remaining 91% were adult. Over the study period from 2019 to 2032, it is anticipated that these numbers will rise, indicating a growing prevalence of the condition by 2032.

• In 2022, the United States contributed to roughly 54% of the total diagnosed prevalent cases of dermatomyositis among the 7MM. Meanwhile, the European Union’s four major countries and the United Kingdom together accounted for nearly 29%, and Japan represented approximately 17%. Projections indicate an expected increase in these cases by 2032.

• The annual incidence of adult dermatomyositis is pegged at 1.9 and 7.7/1,000,000, according to Orphanet et al. (n.d.). Juvenile dermatomyositis (JDM) affects 1 in 50,000 to 1 in 500,000 children under the age of 18

• The present developing pipeline for dermatomyositis shows significant promise, with notable candidates such as Priovant Therapeutics/Pfizer’s brepocitinib (PF06700841), CSL Behring’s HIZENTRA (IgPro20), AstraZeneca’s ULTOMIRIS (ravulizumab/ALXN1210), Argenx’s efgartigimod, Pfizer’s PF-06823859 (dazukibart), and several others.

• Dermatomyositis Intravenous Immune Globulin TrialIn the 16-week ProDERM Trial Group study of adults with dermatomyositis, the proportion of patients who responded with at least a modest improvement based on a composite score of disease activity was considerably higher in the IVIG group than in the placebo group. Thromboembolism and adverse outcomes were linked to IVIG

• In the year 2023, Treatment of juvenile dermatomyositis with abatacept therapy shows promising results. A significant portion of individuals with juvenile dermatomyositis, an uncommon but frequently severe and chronic systemic autoimmune disease, are resistant to treatment and require long-term immunosuppressive therapy. The use of the targeted biologic medication abatacept to treat these individuals has shown potential in a small open-label research that was published in Arthritis and Rheumatology

• Lenabasum, a CB2 agonist that causes inflammation to subside, has been successfully used to treat amyopathic dermatomyositis, according to a recent study published in the Journal of Investigative Dermatology

• Key Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others

• Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others

• The Dermatomyositis epidemiology based on gender analyzed that dermatomyositis is more common in women than in men (2:1)

• The Dermatomyositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dermatomyositis pipeline products will significantly revolutionize the Dermatomyositis market dynamics.

Dermatomyositis Overview

Dermatomyositis is a rare autoimmune disease characterized by inflammation of the muscles and skin. It causes muscle weakness and a distinctive skin rash, typically affecting the face, neck, shoulders, upper chest, elbows, knees, and knuckles. The exact cause is unknown, but it’s believed to involve a combination of genetic predisposition, environmental factors, and an abnormal immune response. 

Get a Free sample for the Dermatomyositis Market Report:

https://www.delveinsight.com/report-store/dermatomyositis-market

Dermatomyositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dermatomyositis Epidemiology Segmentation:

The Dermatomyositis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Dermatomyositis

• Prevalent Cases of Dermatomyositis by severity

• Gender-specific Prevalence of Dermatomyositis

• Diagnosed Cases of Episodic and Chronic Dermatomyositis

Download the report to understand which factors are driving Dermatomyositis epidemiology trends @ Dermatomyositis Epidemiology Forecast

Dermatomyositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dermatomyositis market or expected to get launched during the study period. The analysis covers Dermatomyositis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dermatomyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dermatomyositis Therapies and Key Companies

• Brepocitinib: Priovant Therapeutics, Inc.

• Lenabasum: Corbus Pharmaceuticals

• HIZENTRA: CSL Behring

• Ravulizumab: Alexion

• Lenabasum: Corbus Pharmaceuticals Inc.

• IMO-8400: Idera Pharmaceuticals

• GLPG3667: Galapagos NV

• M5049: EMD Serono

• human immunoglobulin G: CSL Behring

• PF-06823859: Pfizer

• Octagam: Octapharma

• KZR-616: Kezar Life Sciences, Inc.

• GB-0998: Japan Blood Products Organization

• H.P. Acthar Gel: Mallinckrodt

• Adrenocorticotropic Hormone Gel: Mallinckrodt

• tocilizumab: Genentech, Inc.

• Tacrolimus: Astellas Pharma Inc

• Rituximab: Biogen

Discover more about therapies set to grab major Dermatomyositis market share @ Dermatomyositis Treatment Market

Dermatomyositis Market Strengths

• A significant increase in knowledge and understanding of disease pathogenesis has led to the identification of various novel MoAstargeting C5 complement, IFNβ1, FcRn, and others. 

• Established diagnostic and clinical guidelines for adult and juvenile dermatomyositis enable informed treatment and management of patients

Dermatomyositis Market Opportunities

• Better prognostic markers would allow physicians to diagnose and begin treatment at early onset, possibly preventing disease progression. 

• The lack of curative and effective therapies allows pharma players to conduct trials and bring novel, disease-modifying therapies.

Scope of the Dermatomyositis Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others

• Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others

• Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies

• Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Dermatomyositis Unmet Needs, KOL’s views, Analyst’s views, Dermatomyositis Market Access and Reimbursement 

To know more about Dermatomyositis companies working in the treatment market, visit @ Dermatomyositis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Dermatomyositis Market Report Introduction

2. Executive Summary for Dermatomyositis

3. SWOT analysis of Dermatomyositis

4. Dermatomyositis Patient Share (%) Overview at a Glance

5. Dermatomyositis Market Overview at a Glance

6. Dermatomyositis Disease Background and Overview

7. Dermatomyositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Dermatomyositis 

9. Dermatomyositis Current Treatment and Medical Practices

10. Dermatomyositis Unmet Needs

11. Dermatomyositis Emerging Therapies

12. Dermatomyositis Market Outlook

13. Country-Wise Dermatomyositis Market Analysis (2019–2032)

14. Dermatomyositis Market Access and Reimbursement of Therapies

15. Dermatomyositis Market Drivers

16. Dermatomyositis Market Barriers

17.  Dermatomyositis Appendix

18. Dermatomyositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dermatomyositis Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus

The Diffuse Cutaneous Systemic Sclerosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diffuse Cutaneous Systemic Sclerosis pipeline products will significantly revolutionize the Diffuse Cutaneous Systemic Sclerosis market dynamics.  

DelveInsight’s “Diffuse Cutaneous Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diffuse Cutaneous Systemic Sclerosis, historical and forecasted epidemiology as well as the Diffuse Cutaneous Systemic Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Diffuse Cutaneous Systemic Sclerosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Diffuse Cutaneous Systemic Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diffuse Cutaneous Systemic Sclerosis Market Insights

Some of the key facts of the Diffuse Cutaneous Systemic Sclerosis Market Report: 

• The Diffuse Cutaneous Systemic Sclerosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In October 2023, Kyverna Therapeutics revealed that the FDA has approved the third Investigational New Drug (IND) application for KYV-101. This milestone enables Kyverna to commence a Phase I/II open-label, multicenter study of KYV-101. KYV-101 is an autologous fully human anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy designed for addressing diffuse cutaneous systemic sclerosis.

• According to Bergamasco et al. (2022), the documented occurrence of SSc ranged from 7.2 to 33.9 per 100,000 individuals in Europe and from 13.5 to 44.3 per 100,000 individuals in North America.

• Adigun et al. (2022) noted that there is a general prevalence of females in SSc cases, with a female to male ratio of approximately 5:1. Additionally, females typically experience the onset of SSc at a younger age compared to males.

• Key Diffuse Cutaneous Systemic Sclerosis Companies: Kyowa Hakko Kirin, Kadmon Corporation, Sanofi, Emerald Health Pharmaceuticals, Mitsubishi Tanabe Pharma, Horizon Therapeutics, Gesynta Pharma, and others

• Key Diffuse Cutaneous Systemic Sclerosis Therapies: Brodalumab, Belumosudil, EHP-101, MT-7117, HZN-825, GS-248, and others

• The Diffuse Cutaneous Systemic Sclerosis epidemiology based on gender analyzed that females are more affected with Diffuse cutaneous systemic sclerosis than males

Diffuse Cutaneous Systemic Sclerosis Overview

Diffuse Cutaneous Systemic Sclerosis (dcSSc) is a subtype of systemic sclerosis, also known as scleroderma, which is a rare autoimmune disease characterized by excessive collagen production leading to fibrosis in the skin and internal organs. In dcSSc, skin thickening typically affects the trunk, upper arms, thighs, and face, and it can progress rapidly.

Get a Free sample for the Diffuse Cutaneous Systemic Sclerosis Market Report:

https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market

Diffuse Cutaneous Systemic Sclerosis Market  

The dynamics of the Diffuse Cutaneous Systemic Sclerosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034. 

Diffuse Cutaneous Systemic Sclerosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diffuse Cutaneous Systemic Sclerosis Epidemiology Segmentation:

The Diffuse Cutaneous Systemic Sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Diffuse Cutaneous Systemic Sclerosis

• Prevalent Cases of Diffuse Cutaneous Systemic Sclerosis by severity

• Gender-specific Prevalence of Diffuse Cutaneous Systemic Sclerosis

• Diagnosed Cases of Episodic and Chronic Diffuse Cutaneous Systemic Sclerosis

Download the report to understand which factors are driving Diffuse Cutaneous Systemic Sclerosis epidemiology trends @ Diffuse Cutaneous Systemic Sclerosis Epidemiological Insights

Diffuse Cutaneous Systemic Sclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diffuse Cutaneous Systemic Sclerosis market or expected to get launched during the study period. The analysis covers Diffuse Cutaneous Systemic Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diffuse Cutaneous Systemic Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diffuse Cutaneous Systemic Sclerosis Therapies and Key Companies

• Brodalumab: Kyowa Hakko Kirin

• Belumosudil: Kadmon Corporation /Sanofi

• EHP-101: Emerald Health Pharmaceuticals

• MT-7117: Mitsubishi Tanabe Pharma

• HZN-825: Horizon Therapeutics

• GS-248: Gesynta Pharma

To know more about Diffuse Cutaneous Systemic Sclerosis treatment, visit @ Diffuse Cutaneous Systemic Sclerosis Medications

Diffuse Cutaneous Systemic Sclerosis Market Strengths

• Advances in medical research have resulted in a growing understanding of the disease, enabling targeted treatment approaches. 

• The expected launch of potential emerging therapies is anticipated to drive the dcSSc market.

Diffuse Cutaneous Systemic Sclerosis Market Opportunities

• Ongoing research into the underlying mechanisms of dcSSc may lead to the development of new and more effective treatment options. 

• The current treatment options are very few for treating patients with dcSSc, which open a platform of new therapies to boon the market of dcSSC.

• Establishment of National Registry for Ichthyosis to promote the search for basic defects, improve methods of diagnosis, and develop effective methods of treatment and/or prevention.

Scope of the Diffuse Cutaneous Systemic Sclerosis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Diffuse Cutaneous Systemic Sclerosis Companies: Kyowa Hakko Kirin, Kadmon Corporation, Sanofi, Emerald Health Pharmaceuticals, Mitsubishi Tanabe Pharma, Horizon Therapeutics, Gesynta Pharma, and others

• Key Diffuse Cutaneous Systemic Sclerosis Therapies: Brodalumab, Belumosudil, EHP-101, MT-7117, HZN-825, GS-248, and others

• Diffuse Cutaneous Systemic Sclerosis Therapeutic Assessment: Diffuse Cutaneous Systemic Sclerosis current marketed and Diffuse Cutaneous Systemic Sclerosis emerging therapies

• Diffuse Cutaneous Systemic Sclerosis Market Dynamics: Diffuse Cutaneous Systemic Sclerosis market drivers and Diffuse Cutaneous Systemic Sclerosis market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Diffuse Cutaneous Systemic Sclerosis Unmet Needs, KOL’s views, Analyst’s views, Diffuse Cutaneous Systemic Sclerosis Market Access and Reimbursement 

Discover more about therapies set to grab major Diffuse Cutaneous Systemic Sclerosis market share @ Diffuse Cutaneous Systemic Sclerosis market forecast

Table of Contents 

1. Diffuse Cutaneous Systemic Sclerosis Market Report Introduction

2. Executive Summary for Diffuse Cutaneous Systemic Sclerosis

3. SWOT analysis of Diffuse Cutaneous Systemic Sclerosis

4. Diffuse Cutaneous Systemic Sclerosis Patient Share (%) Overview at a Glance

5. Diffuse Cutaneous Systemic Sclerosis Market Overview at a Glance

6. Diffuse Cutaneous Systemic Sclerosis Disease Background and Overview

7. Diffuse Cutaneous Systemic Sclerosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Diffuse Cutaneous Systemic Sclerosis 

9. Diffuse Cutaneous Systemic Sclerosis Current Treatment and Medical Practices

10. Diffuse Cutaneous Systemic Sclerosis Unmet Needs

11. Diffuse Cutaneous Systemic Sclerosis Emerging Therapies

12. Diffuse Cutaneous Systemic Sclerosis Market Outlook

13. Country-Wise Diffuse Cutaneous Systemic Sclerosis Market Analysis (2020–2034)

14. Diffuse Cutaneous Systemic Sclerosis Market Access and Reimbursement of Therapies

15. Diffuse Cutaneous Systemic Sclerosis Market Drivers

16. Diffuse Cutaneous Systemic Sclerosis Market Barriers

17.  Diffuse Cutaneous Systemic Sclerosis Appendix

18. Diffuse Cutaneous Systemic Sclerosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Cutaneous Systemic Sclerosis Market to Exhibit Rapid Growth Rate During the Forecast Period (2024-2034), Investigates DelveInsight | Kyowa Hakko Kirin, Kadmon Corporation, Sanofi, Emerald

DelveInsight’s “Cutaneous Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cutaneous Squamous Cell Carcinoma, historical and forecasted epidemiology as well as the Cutaneous Squamous Cell Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cutaneous Squamous Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cutaneous Squamous Cell Carcinoma Market Forecast

Some of the key facts of the Cutaneous Squamous Cell Carcinoma Market Report: 

• The Cutaneous Squamous Cell Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In January 2024, Medison Pharma has disclosed a partnership with Regeneron Pharmaceuticals to distribute LIBTAYO across specific European regions and other global markets.

• In December 2023, Replimune has provided preliminary findings from the primary analysis of the CERPASS clinical trial concerning advanced cutaneous squamous cell carcinoma (CSCC).

• In March 2023, Checkpoint declared that the US FDA had acknowledged its BLA submission and established a Prescription Drug User Fee Act (PDUFA) goal date slated for January 2024.

• As per The Skin Cancer Foundation (2023), it is approximated that 1 million instances of CSCC are identified annually, equating to roughly 115 cases per hour. Out of these, about 40,000 cases will progress to an advanced stage. In the US alone, an estimated 15,000 individuals succumb to CSCC annually, a figure that surpasses the projected deaths from melanoma.

• As reported by Ogata et al. (2023), basal cell carcinoma and squamous cell carcinoma exhibited the highest incidences among skin cancers in Japan, with rates of 3.63 and 3.40 per 100,000 persons, respectively, according to the WHO model.

• Key Cutaneous Squamous Cell Carcinoma Companies: Incyte Corporation, Melanoma Institute Australia, Replimune Inc., Stanford University, Regeneron Pharmaceuticals, Shanghai Henlius Biotech, Merck Sharp & Dohme LLC, Philogen S.p.A., Queensland Health, Sanofi, and others

• Key Cutaneous Squamous Cell Carcinoma Therapies: INCB099280, Nivolumab, Atezolizumab, cemiplimab, HLX07, MK-3475A, L19IL2 +L19TNF, Pembrolizumab, THOR-707, and others

• The Cutaneous Squamous Cell Carcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cutaneous Squamous Cell Carcinoma pipeline products will significantly revolutionize the Cutaneous Squamous Cell Carcinoma market dynamics.

Cutaneous Squamous Cell Carcinoma Overview

Cutaneous Squamous Cell Carcinoma (cSCC) is a type of skin cancer that arises from the squamous cells in the outermost layer of the skin, known as the epidermis. It typically develops on areas of the skin that are frequently exposed to the sun, such as the face, ears, neck, scalp, arms, and hands. However, it can also occur on other parts of the body, including scars, chronic wounds, and areas of previous radiation therapy.

Get a Free sample for the Cutaneous Squamous Cell Carcinoma Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/cutaneous-squamous-cell-carcinoma-cscc-market

Cutaneous Squamous Cell Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cutaneous Squamous Cell Carcinoma Epidemiology Segmentation:

The Cutaneous Squamous Cell Carcinoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Cutaneous Squamous Cell Carcinoma

• Prevalent Cases of Cutaneous Squamous Cell Carcinoma by severity

• Gender-specific Prevalence of Cutaneous Squamous Cell Carcinoma

• Diagnosed Cases of Episodic and Chronic Cutaneous Squamous Cell Carcinoma

Download the report to understand which factors are driving Cutaneous Squamous Cell Carcinoma epidemiology trends @ Cutaneous Squamous Cell Carcinoma Epidemiology Forecast

Cutaneous Squamous Cell Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cutaneous Squamous Cell Carcinoma market or expected to get launched during the study period. The analysis covers Cutaneous Squamous Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cutaneous Squamous Cell Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cutaneous Squamous Cell Carcinoma Therapies and Key Companies

• INCB099280: Incyte Corporation

• Nivolumab: Melanoma Institute Australia

• Atezolizumab: Stanford University

• cemiplimab: Regeneron Pharmaceuticals

• HLX07: Shanghai Henlius Biotech

• MK-3475A: Merck Sharp & Dohme LLC

• L19IL2 +L19TNF: Philogen S.p.A.

• Pembrolizumab: Queensland Health

• THOR-707: Sanofi

Discover more about therapies set to grab major Cutaneous Squamous Cell Carcinoma market share @ Cutaneous Squamous Cell Carcinoma Treatment Landscape 

Cutaneous Squamous Cell Carcinoma Market Strengths

• Ongoing research and advancements in the understanding of CSCC may lead to the development of new treatment options and targeted therapies.

• Improvements in diagnostic tools, such as imaging techniques and biopsy methods, contribute to early and accurate diagnosis, allowing for timely intervention.

Cutaneous Squamous Cell Carcinoma Market Opportunities

• Early detection of precursor lesions, appropriate diagnosis, and staging of CSCCs is key to providing patients with appropriate prognostic information.

• Continued advancements in immunotherapy may offer new and more effective treatment options for CSCC, harnessing the body’s immune system to fight cancer.

Scope of the Cutaneous Squamous Cell Carcinoma Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Cutaneous Squamous Cell Carcinoma Companies: Incyte Corporation, Melanoma Institute Australia, Replimune Inc., Stanford University, Regeneron Pharmaceuticals, Shanghai Henlius Biotech, Merck Sharp & Dohme LLC, Philogen S.p.A., Queensland Health, Sanofi, and others

• Key Cutaneous Squamous Cell Carcinoma Therapies: INCB099280, Nivolumab, Atezolizumab, cemiplimab, HLX07, MK-3475A, L19IL2 +L19TNF, Pembrolizumab, THOR-707, and others

• Cutaneous Squamous Cell Carcinoma Therapeutic Assessment: Cutaneous Squamous Cell Carcinoma current marketed and Cutaneous Squamous Cell Carcinoma emerging therapies

• Cutaneous Squamous Cell Carcinoma Market Dynamics: Cutaneous Squamous Cell Carcinoma market drivers and Cutaneous Squamous Cell Carcinoma market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Cutaneous Squamous Cell Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Cutaneous Squamous Cell Carcinoma Market Access and Reimbursement 

To know more about Cutaneous Squamous Cell Carcinoma companies working in the treatment market, visit @ Cutaneous Squamous Cell Carcinoma Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Cutaneous Squamous Cell Carcinoma Market Report Introduction

2. Executive Summary for Cutaneous Squamous Cell Carcinoma

3. SWOT analysis of Cutaneous Squamous Cell Carcinoma

4. Cutaneous Squamous Cell Carcinoma Patient Share (%) Overview at a Glance

5. Cutaneous Squamous Cell Carcinoma Market Overview at a Glance

6. Cutaneous Squamous Cell Carcinoma Disease Background and Overview

7. Cutaneous Squamous Cell Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Cutaneous Squamous Cell Carcinoma 

9. Cutaneous Squamous Cell Carcinoma Current Treatment and Medical Practices

10. Cutaneous Squamous Cell Carcinoma Unmet Needs

11. Cutaneous Squamous Cell Carcinoma Emerging Therapies

12. Cutaneous Squamous Cell Carcinoma Market Outlook

13. Country-Wise Cutaneous Squamous Cell Carcinoma Market Analysis (2019–2032)

14. Cutaneous Squamous Cell Carcinoma Market Access and Reimbursement of Therapies

15. Cutaneous Squamous Cell Carcinoma Market Drivers

16. Cutaneous Squamous Cell Carcinoma Market Barriers

17.  Cutaneous Squamous Cell Carcinoma Appendix

18. Cutaneous Squamous Cell Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous Squamous Cell Carcinoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Incyte Crp, Merck Sharp, Regeneron Pharma, Replimune Inc

The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Chronic Wounds Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.

Some of the key takeaways from the Chronic Wounds Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Wounds treatment therapies with a considerable amount of success over the years. 

• Chronic Wounds companies working in the treatment market are Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE, and others, are developing therapies for the Chronic Wounds treatment 

• Emerging Chronic Wounds therapies in the different phases of clinical trials are- ADRCs, ON101, EscharEx, SkinTE, and others are expected to have a significant impact on the Chronic Wounds market in the coming years.   

• In March 2024, SOLASCURE revealed the release of its CLEANVLU Phase IIa clinical trial findings in the esteemed International Wound Journal, a prominent publication in the wound care field. SolasCure’s debut investigational solution, Aurase Wound Gel, comprises a hydrogel that dispenses tarumase (temporary INN), an engineered enzyme sourced from medical maggots. The gel is designed to facilitate wound healing by promoting debridement and preparing the wound bed for recovery.

• In February 2024, Cynata Therapeutics Limited has concluded the preliminary assessment of wound size across the initial 16 participants in its phase 1 clinical study of CYP-006TK for diabetic foot ulcers (DFU), spanning up to the 10-week post-treatment evaluation.

• In February 2024, PolarityTE has commenced a multi-center, prospective, randomized controlled trial to assess the effectiveness and safety of SkinTE® in treating Wagner 1 diabetic foot ulcers (DFUs), known as COVER DFUs II. The trial aims to evaluate the closure achieved through vascularized epithelial regeneration with SkinTE® for Wagner grade 1 DFUs.

• In May 2022, PolarityTE revealed that SkinTE has been awarded a Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) under the company’s open Investigational New Drug (IND) application.

Chronic Wounds Overview

Chronic wounds are injuries to the skin that fail to progress through the normal stages of healing within an expected timeframe, typically within three months. These wounds often remain open for an extended period, leading to persistent inflammation and delayed healing. Common types of chronic wounds include pressure ulcers, diabetic foot ulcers, venous ulcers, and arterial ulcers.

Get a Free Sample PDF Report to know more about Chronic Wounds Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-wounds-pipeline-insight

Emerging Chronic Wounds Drugs Under Different Phases of Clinical Development Include:

• ADRCs: Paracrine, Inc

• ON101: Oneness Biotech

• EscharEx: MediWound

• SkinTE: PolarityTE

Chronic Wounds Route of Administration

Chronic Wounds pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Chronic Wounds Molecule Type

Chronic Wounds Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Chronic Wounds Pipeline Therapeutics Assessment

• Chronic Wounds Assessment by Product Type

• Chronic Wounds By Stage and Product Type

• Chronic Wounds Assessment by Route of Administration

• Chronic Wounds By Stage and Route of Administration

• Chronic Wounds Assessment by Molecule Type

• Chronic Wounds by Stage and Molecule Type

DelveInsight’s Chronic Wounds Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Chronic Wounds product details are provided in the report. Download the Chronic Wounds pipeline report to learn more about the emerging Chronic Wounds therapies

Some of the key companies in the Chronic Wounds Therapeutics Market include:

Key companies developing therapies for Chronic Wounds are – ConvaTec Inc., Smith & Nephew, 3M, and others.

Chronic Wounds Pipeline Analysis:

The Chronic Wounds pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Wounds with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Wounds Treatment.

• Chronic Wounds key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Wounds Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Wounds market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Wounds drugs and therapies

Chronic Wounds Pipeline Market Drivers

• The drivers of the chronic wound care market include factors such as the increasing prevalence of chronic diseases like diabetes, cancer, and autoimmune diseases, the growing elderly population, the rise in sports related injuries, and the need for advanced wound care products and treatments.

Chronic Wounds Pipeline Market Barriers

• With a limited patient population, pharmaceutical companies face challenges in recouping the substantial expenses incurred during the research, development, and clinical trial phases of new treatments.

Scope of Chronic Wounds Pipeline Drug Insight    

• Coverage: Global

• Key Chronic Wounds Companies: Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE, and others

• Key Chronic Wounds Therapies: ADRCs, ON101, EscharEx, SkinTE, and others

• Chronic Wounds Therapeutic Assessment: Chronic Wounds current marketed and Chronic Wounds emerging therapies

• Chronic Wounds Market Dynamics: Chronic Wounds market drivers and Chronic Wounds market barriers 

Request for Sample PDF Report for Chronic Wounds Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Wounds Report Introduction

2. Chronic Wounds Executive Summary

3. Chronic Wounds Overview

4. Chronic Wounds- Analytical Perspective In-depth Commercial Assessment

5. Chronic Wounds Pipeline Therapeutics

6. Chronic Wounds Late Stage Products (Phase II/III)

7. Chronic Wounds Mid Stage Products (Phase II)

8. Chronic Wounds Early Stage Products (Phase I)

9. Chronic Wounds Preclinical Stage Products

10. Chronic Wounds Therapeutics Assessment

11. Chronic Wounds Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Wounds Key Companies

14. Chronic Wounds Key Products

15. Chronic Wounds Unmet Needs

16 . Chronic Wounds Market Drivers and Barriers

17. Chronic Wounds Future Perspectives and Conclusion

18. Chronic Wounds Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Wounds Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE

“Celiac Disease Pipeline”

(New York, United States) “Celiac Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ Celiac Disease Pipeline Outlook

Some of the key takeaways from the Celiac Disease Pipeline Report:

• Celiac Disease Companies across the globe are diligently working toward developing novel Celiac Disease treatment therapies with a considerable amount of success over the years. 
• Celiac Disease companies working in the treatment market are 9Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others, are developing therapies for the Celiac Disease treatment 

• Emerging Celiac Disease therapies in the different phases of clinical trials are- AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others are expected to have a significant impact on the Celiac Disease market in the coming years.
• On March 2024, Takeda announced results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet
• On March 2024, Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA announced results of a Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease.
• On December 2023, Topas Therapeutics GmbH announced results of a Double-blind, Randomized, Placebo-controlled, Phase 2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamic (PD) Effects of Two Infusions of Escalating Doses of TPM502 in Adults Diagnosed With Celiac Disease.
• On November 2023, Chugai Pharmaceutical announced results of a Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study).
• On September 2023, Regeneron Pharmaceuticals announced results of a study based on T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge.

Celiac Disease Overview

Celiac disease is an autoimmune disorder triggered by the ingestion of gluten—a protein found in wheat, barley, and rye—in genetically predisposed individuals. When someone with celiac disease consumes gluten, their immune system responds by damaging the lining of the small intestine. This damage impairs the absorption of nutrients from food, leading to various symptoms and potential long-term complications.

Symptoms of celiac disease can vary widely and may include gastrointestinal issues like diarrhea, abdominal pain, bloating, and constipation, as well as non-gastrointestinal symptoms such as fatigue, joint pain, skin rashes, and neurological problems.

Diagnosis typically involves blood tests to check for specific antibodies associated with celiac disease, followed by confirmation through a biopsy of the small intestine to assess for characteristic damage to the intestinal lining.

The primary treatment for celiac disease is strict adherence to a gluten-free diet, which involves avoiding all foods containing wheat, barley, and rye. This typically leads to symptom resolution, intestinal healing, and prevention of complications. Additionally, individuals with celiac disease may benefit from nutritional supplementation and regular monitoring by healthcare professionals to ensure optimal management of the condition and prevent potential deficiencies or complications. 

Get a Free Sample PDF Report to know more about Celiac Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Emerging Celiac Disease Drugs Under Different Phases of Clinical Development Include:

• AMY02 : AMYRA Biotech AG
• EQ102 : Equillium Bio.
• DONQ52 : Chugai Pharmaceutical Co., Ltd.
• CALY-002 : Calypso Biotech
• Latiglutenase : ImmunogenX, Inc.
• Ordesekimab : Amgen Inc.

Celiac Disease Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Celiac Disease Molecule Type

Celiac Disease Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule 

Celiac Disease Pipeline Therapeutics Assessment

• Celiac Disease Assessment by Product Type
• Celiac Disease By Stage and Product Type
• Celiac Disease Assessment by Route of Administration
• Celiac Disease By Stage and Route of Administration
• Celiac Disease Assessment by Molecule Type
• Celiac Disease by Stage and Molecule Type

DelveInsight’s Celiac Disease Report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Celiac Disease product details are provided in the report. Download the Celiac Disease pipeline report to learn more about the emerging Celiac Disease therapies- https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Some of the key companies in the Celiac Disease Therapeutics Market include:

Key companies developing therapies for Celiac Disease are – 9 Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others.

Celiac Disease Pipeline Analysis:

The Celiac Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
• Celiac Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Celiac Disease drugs and therapies – https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Celiac Disease Pipeline Market Drivers

Increasing prevalence of Celiac Disease, increasing R&D activities, no Approved Therapy are some of the important factors that are fueling the Celiac Disease Market.

Celiac Disease Pipeline Market Barriers

However, limited patient awareness about the disease, poor Patient Compliance and other factors are creating obstacles in the Celiac Disease Market growth.

Scope of Celiac Disease Pipeline Drug Insight    

• Coverage: Global
• Key Celiac Disease Companies: 9Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others
• Key Celiac Disease Therapies: AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others
• Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
• Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers 

Request for Sample PDF Report for Celiac Disease Pipeline Assessment and clinical trials – https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Table of Contents 

1. Celiac Disease Report Introduction

2. Celiac Disease Executive Summary

3. Celiac Disease Overview

4. Celiac Disease- Analytical Perspective In-depth Commercial Assessment

5. Celiac Disease Pipeline Therapeutics

6. Celiac Disease Late Stage Products (Phase II/III)

7. Celiac Disease Mid Stage Products (Phase II)

8. Celiac Disease Early Stage Products (Phase I)

9. Celiac Disease Preclinical Stage Products

10. Celiac Disease Therapeutics Assessment

11. Celiac Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Celiac Disease Key Companies

14. Celiac Disease Key Products

15. Celiac Disease Unmet Needs

16 . Celiac Disease Market Drivers and Barriers

17. Celiac Disease Future Perspectives and Conclusion

18. Celiac Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Celiac Disease Pipeline Analysis 2024: Clinical Trials, FDA Approvals, Emerging Therapies, ROA, MOA and Treatment Outlook by DelveInsight | Amgen, AMYRA Biotec, Equillium Bio, Chugai Pharmaceutical

“Diabetic Kidney Disease Market”

(Albany, USA) DelveInsight’s Diabetic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, diabetic kidney disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the Diabetic Kidney Disease Market Report

• According to DelveInsight’s analysis, the market size for diabetic kidney disease reached USD 7.2 billion in 2023 across the 7MM and is expected to grow with a significant CAGR by 2034.
• DelveInsight’s analysis reveals that the overall prevalent population of diabetic kidney disease in the 7MM was reported as ~33 million in 2023. 
• Leading diabetic kidney disease companies such as Boehringer Ingelheim, Daiichi Sankyo, ProKidney, Chinook Therapeutics (a Novartis company), AbbVie, Inversago Pharma (a Novo Nordisk Company), Mineralys Therapeutics, CSL Behring, Teijin Pharma, Dimerix, Chugai Pharmaceutical, Lisata Therapeutics and others are developing novel diabetic kidney disease drugs that can be available in the diabetic kidney disease market in the coming years.
• The promising diabetic kidney disease therapies in the pipeline include Esaxerenone (CS-3150), REACT (Renal Autologous Cell Therapy), Zibotentan + dapagliflozin, BI 690517 ± empagliflozin, Atrasentan, Tozorakimab (MEDI3506) + dapagliflozin, INV-202, and others.

Discover which therapies are expected to grab the major diabetic kidney disease market share @ Diabetic Kidney Disease Market Report

Diabetic Kidney Disease Overview

Diabetic kidney disease (DKD), also referred to as diabetic nephropathy (DN), is a clinical condition marked by persistent albuminuria and a gradual decline in renal function. This term implies the existence of a recognizable pattern of glomerular disease. Typically, Diabetic Kidney Disease is linked with high blood pressure, leading to increased cardiovascular risks and mortality. The causes of DKD are intricate and likely involve various factors, with hyperglycemia being the primary contributor. Initial stages of Diabetic Kidney Disease may be asymptomatic, but as renal function diminishes, the accumulation of toxic wastes can lead to symptoms such as nausea, vomiting, loss of appetite, hiccups, and weight gain due to fluid retention. Untreated cases may progress to heart failure and pulmonary edema.

Detecting and diagnosing Diabetic Kidney Disease poses challenges. Screening and renal biopsy are the main diagnostic methods used to identify Diabetic Kidney Disease in patients. In instances of nonalbuminuric DKD, other potential diagnoses considered include ischemic nephropathy, dysproteinemia, and tubulointerstitial nephritis (TIN).

Diabetic Kidney Disease Epidemiology Segmentation

Among the 7MM, the United States accounted for the highest number of diagnosed prevalent cases of DKD, i.e., ~45% of the total cases in the 7MM in 2023.

Among EU4 and the UK, Germany accounted for the largest number of DKD cases, whereas France accounted for the lowest number of cases in 2023.

The diabetic kidney disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Diabetes
• Total Prevalent Cases of Diabetic Kidney Disease
• Total Diagnosed Prevalent Cases of Diabetic Kidney Disease
• Age-specific Cases of Diabetic Kidney Disease
• Stage-specific Cases of Diabetic Kidney Disease

Request for Sample Report @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-market

Diabetic Kidney Disease Treatment Market 

The primary approach to treating DKD involves the reduction of blood pressure, as even a slight elevation in blood pressure can rapidly exacerbate kidney disease. Additionally, it is crucial to manage blood sugar levels to decelerate the progression of diabetic nephropathy. Fundamental methods for lowering blood pressure encompass weight loss, reduced salt intake, abstaining from alcohol and tobacco, and engaging in regular exercise.

The preferred medications for blood pressure management often include angiotensin-converting enzyme (ACE) inhibitors. Capoten (captopril), unlike many ACE inhibitors, is not a prodrug. It competes with AT-I for ACE binding, hindering the enzymatic breakdown of angiotensin I (AT-I) into angiotensin II (AT-II), consequently heightening plasma renin activity. Another medication, enalapril, is an inactive prodrug that undergoes hepatic transformation to generate enalaprilat, its active form. Enalaprilat acts on the Renin-Angiotensin-Aldosterone System (RAAS) to impede ACE, leading to the suppression of RAAS and exhibiting antihypertensive effects in individuals with low-renin hypertension.

In September 2019, the US Food and Drug Administration (FDA) approved the first therapeutic drug designed to treat DKD, INVOKANA (canagliflozin). This medication, categorized as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, plays a crucial role in the majority of glucose reabsorption from the tubular lumen. Canagliflozin inhibits SGLT2, resulting in a decrease in the reabsorption of filtered glucose, a reduction in the renal threshold for glucose (RTG), and consequently, an increase in urinary glucose excretion (UGE). Furthermore, in August 2019, the European Medicines Agency (EMA) accepted the submission for the extension of its license.

To know more about diabetic kidney disease treatment guidelines, visit @ Diabetic Kidney Disease Market Report

Diabetic Kidney Disease Pipeline Therapies and Key Companies

• MINNEBRO (ESAXERENONE/CS-3150): DAIICHI SANKYO
• REACT (RENAL AUTOLOGOUS CELL THERAPY): PROKIDNEY
• ZIBOTENTAN + DAPAGLIFLOZIN: ASTRAZENECA
• VYLEESI (BREMELANOTIDE): PALATIN
• TOZORAKIMAB (MEDI3506) + DAPAGLIFLOZIN: ASTRAZENECA
• ATRASENTAN: CHINOOK THERAPEUTICS/NOVARTIS
• LORUNDROSTAT: MINERALYS THERAPEUTICS
• BI 690517 + EMPAGLIFLOZIN: BOEHRINGER INGELHEIM
• INV-202: INVERSAGO PHARMA

Learn more about the FDA-approved drugs for diabetic kidney disease @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-market

Diabetic Kidney Disease Market Dynamics

The dynamics of the DKD market are expected to change in the coming years. The global rise in diabetes prevalence has contributed significantly to the surge in DKD cases, creating a substantial patient population in need of effective treatments. As awareness about the complications associated with diabetes, including kidney disease, increases, there is a growing demand for therapeutic interventions that specifically target DKD. Additionally, advancements in diagnostic technologies enable earlier and more accurate detection of kidney disease in diabetic patients, fostering a proactive approach to management. 

Furthermore, many potential therapies are being investigated for the treatment of DKD, and it is safe to predict that the treatment space will significantly impact the DKD market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the diabetic kidney disease market in the 7MM.

However several factors may impede the growth of the DKD market. One of the primary challenges is the complexity of the disease itself. DKD is intricately linked to diabetes, a condition with multifaceted causes and manifestations. This complexity makes it challenging to develop targeted and effective treatments.

Moreover, DKD treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the DKD market growth may be offset by failures and discontinuation of emerging therapies. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Diabetic Kidney Disease market growth.

A deeper understanding of the molecular mechanisms of DKD onset and progression is necessary for the development of new and innovative treatments for DKD. Furthermore, as DKD often goes undiagnosed due to its initial lack of symptoms, the use of advanced predictive tests for early detection can augment physicians’ capacity to make well-informed treatment decisions. This, in turn, can result in improved clinical outcomes and streamline more effective therapeutic interventions.

Scope of the Diabetic Kidney Disease Market Report

• Study Period: 2020–2034
• Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
• Diabetic Kidney Disease Market CAGR (2020–2034): 6.5 %
• Diabetic Kidney Disease Market Size in 2023: USD 7.2 Billion
• Key Diabetic Kidney Disease Companies: Johnson & Johnson, Mitsubishi Tanabe Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Daiichi Sankyo, ProKidney, Chinook Therapeutics (a Novartis company), AbbVie, Inversago Pharma (a Novo Nordisk Company), Mineralys Therapeutics, CSL Behring, Teijin Pharma, Dimerix, Chugai Pharmaceutical, Lisata Therapeutics and others
• Key Pipeline Diabetic Kidney Disease Therapies: MINNEBRO (ESAXERENONE/CS-3150), REACT (RENAL AUTOLOGOUS CELL THERAPY), ZIBOTENTAN + DAPAGLIFLOZIN, VYLEESI (BREMELANOTIDE), TOZORAKIMAB (MEDI3506) + DAPAGLIFLOZIN, ATRASENTAN, LORUNDROSTAT, BI 690517 + EMPAGLIFLOZIN, INV-202, and others
• Therapeutic Assessment: Diabetic Kidney Disease current marketed and emerging therapies
• Diabetic Kidney Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Diabetic Kidney Disease Drugs, Conjoint Analysis and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Diabetic Kidney Disease Market Access and Reimbursement

Discover more about diabetic kidney disease drugs in development @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-market

Table of Contents

1. Diabetic Kidney Disease Key Insights

2. Diabetic Kidney Disease Report Introduction

3. Diabetic Kidney Disease Overview at a Glance

4. Diabetic Kidney Disease Executive Summary

5. Diabetic Kidney Disease Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

8. Diabetic Kidney Disease Treatment and Management

9. Diabetic Kidney Disease Guidelines

10. Diabetic Kidney Disease Epidemiology and Patient Population

11. Patient Journey

12. Key Endpoints in Diabetic Kidney Disease

13. Diabetic Kidney Disease Marketed Drugs

14. Diabetic Kidney Disease Emerging Drugs

15. 7MM Diabetic Kidney Disease Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. Unmet Needs

19. SWOT Analysis

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Kidney Disease Market is anticipated to Grow at a CAGR of ~6.5% by 2034, analyzes DelveInsight | Boehringer Ingelheim, Daiichi Sankyo, ProKidney, Chinook Therapeutics, AbbVie,Inversago Pharma